共 50 条
- [1] SOHO State of the Art Updates and Next Questions: Myelofibrosis CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 191 - 199
- [2] SOHO State of the Art Updates and Next Questions: IDH Inhibition CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (09): : 567 - 572
- [3] SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (02): : 81 - 90
- [4] SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 333 - 339
- [5] SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : 133 - 139
- [6] SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (04): : 232 - 237
- [7] SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (08): : 561 - 574
- [8] SOHO State of the Art Updates and Next Questions | Treatment of Richter's Transformation CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : 786 - 799
- [9] SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 641 - 649
- [10] SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (04): : 210 - 223